High-affinity σ1 protein agonist reduces clinical and pathological signs of experimental autoimmune encephalomyelitis.

@article{Oxombre2015HighaffinityP,
  title={High-affinity σ1 protein agonist reduces clinical and pathological signs of experimental autoimmune encephalomyelitis.},
  author={B{\'e}n{\'e}dicte Oxombre and Catalina Lee-Chang and Alain Duhamel and Marie Toussaint and Martin Giroux and Marion Donnier-Mar{\'e}chal and Pascal Carato and Didier Lefranc and H{\'e}l{\`e}ne Z{\'e}phir and Lionel Prin and Patricia Melnyk and Patrick Vermersch},
  journal={British journal of pharmacology},
  year={2015},
  volume={172 7},
  pages={1769-82}
}
BACKGROUND AND PURPOSE Selective agonists of the sigma-1 receptor (σ1 protein) are generally reported to protect against neuronal damage and modulate oligodendrocyte differentiation. Human and rodent lymphocytes possess saturable, high-affinity binding sites for compounds binding to the σ1 protein and potential immunomodulatory properties have been described for σ1 protein ligands. Experimental autoimmune encephalomyelitis (EAE) is recognized as a valuable model of the inflammatory aspects of… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS